Abstract
During the development and organogenesis of all multicellular organisms, cell fate decisions determine whether cells undergo proliferation, differentiation, or aging. Two independent stress kinase signaling pathways, p38-MAPK, and JNKs, have evolved that relay developmental and environmental cues to determine cell responses. Although multiple stimuli can activate these two stress kinase pathways, the functional interactions and molecular cross-talks between these common second signaling cascades are poorly elucidated. Here we report that JNK and p38-MAPK pathways antagonistically control cellular senescence, oncogenic transformation, and proliferation in primary mouse embryonic fibroblasts (MEFs). Similarly, genetic inactivation of the JNK pathway results in impaired proliferation of fetal hepatoblasts in vitro and defective adult liver regeneration in vivo, which is rescued by inhibition of the p38-MAPK pathway. Thus, the balance between the two stress-signaling pathways, MKK7-JNK and MKK3/6-p38-MAPK, determines cell fate and links environmental and developmental stress to cell cycle arrest, senescence, oncogenic transformation, and adult tissue regeneration.
Similar content being viewed by others
Main
Developmental programs and environmental agents trigger distinct and evolutionarily conserved kinases that relay stress signals mediating proliferation, regeneration, transformation, survival, death, senescence, or cell cycle arrest. The mitogen-activated protein kinases (MAPKs) are a family of kinases that transduce signals from the cell membrane to the nucleus in response to a wide range of stimuli, including stress.1, 2, 3, 4 Among the MAPK signaling pathways, JNKs and p38-MAPKs were identified to be activated in response to a variety of cellular and environmental stresses such as changes in osmolarity, DNA damage, heat shock, ischemia, cytokines, UV irradiation, or oxidative stress.2, 3, 4 JNKs are directly activated by the two upstream kinases MKK4 and MKK7. Once activated, JNKs regulate gene transcription via phosphorylation of transcription factors, such as Jun.2, 3, 4, 5 In contrast, p38-MAPKs are activated by MKK3 and MKK6.2, 4 These two stress pathways participate in many different intracellular signaling cascades that control a spectrum of cellular processes, including proliferation, differentiation, or apoptosis.
Although JNK and p38-MAPK have the same phylogenic origin,1 it is not known why two genetically independent stress-signaling pathways have evolved in evolution. Here we show that the two stress pathways, MKK7-JNK and MKK3/6-p38-MAPK, oppositely control cellular proliferation, regeneration, senescence, and oncogenic transformation, and that qthe balance between two pathways determines cell fates in response to a variety of stress stimuli.
Results
Antagonistic effect of JNK and p38-MAPK pathways in cell proliferation
Mouse embryonic fibroblasts (MEFs) isolated from mkk7 mutant embryos display impaired JNK and Jun activation, reduced cell proliferation, premature senescence, as well as augmented susceptibility to stress-induced aging (Figure 1 and Wada et al.6). In contrast, activation of p38-MAPK can also result in premature senescence of MEFs,7 whereas pharmacological p38-MAPK inhibition induces increased cell proliferation,8 To assess functional hierarchies and potential molecular cross-talks between the JNK and p38-MAPK stress pathways in cell fate decisions, we tested the effects of p38-MAPK modulation in mkk7−/− MEFs. Surprisingly, inhibition of p38-MAPKα/β using the selective inhibitor SB202190 restored the proliferation of mkk7-deficient MEFs to that of MKK7-expressing control cells (Figure 1a). To further confirm whether the reversal effects of cell proliferation are indeed p38-MAPK dependent, we introduced dominant-negative forms of MKK3 and MKK6 (MKK3-DN and MKK6-DN) into mkk7−/− MEFs to genetically inactivate p38-MAPK activity. Similar to SB202190, both MKK3-DN and MKK6-DN restored cell proliferation in mkk7-deficient cells (Figure 1b). Expression of MKK3-DN and MKK6-DN in MEFs inhibited UV-induced p38-MAPK activation as measured by ATF2 phosphorylation, but had no substantial effect on UV-induced JNK activation (Supplementary Figure 1a). Thus, inhibition of the p38-MAPK pathway can rescue the proliferative defect observed in mkk7−/− MEFs.
JNK and p38-MAPK antagonistically control cellular senescence
To examine whether these antagonistic effects are limited to cell proliferation, we examined other MKK7-JNK-dependent cell fate responses such as senescence.6 Treatment of mkk7−/− MEFs with the selective p38-MAPKα/β inhibitor SB202190, as well as overexpression of MKK3-DN and MKK6-DN indeed prevented premature senescence (Figure 1c and d). Treatment of wild-type cells with H2O2 or UV radiation resulted in premature senescence phenotype that is markedly enhanced in mkk7−/− MEFs (Figure 1e). Importantly, inhibition of p38-MAPKα/β abolished premature senescence in both mkk7+/− and mkk7−/− MEFs following treatment with H2O2 and UV (Figure 1e). These results show that MKK7-JNK and MKK3/6-p38-MAPK pathways play opposite roles in multiple cell fate responses: inactivation of the MKK7-JNK pathway results in defective proliferation and premature senescence; in contrast, inhibition of MKK3/6-p38-MAPK pathway triggers cell proliferation and markedly suppresses the cellular aging response. Importantly, inhibition of the p38-MAPK pathway allows mkk7-null cells to exit the cell cycle block and rescues mkk7−/− MEFs from a premature aging response in response to environmental stress.
The JNK and p38-MAPK stress pathways balance oncogenic transformation
It has been shown that cell proliferation, senescence, and cancer are closely linked at the molecular level.9 Both MKK7-JNK-Jun as well as MMK3/MMK6-p38-MAPK signaling have been implicated in multiple cancers in humans.2, 10 Since MKK7-JNK and MKK3/6-p38-MAPK pathways exhibit antagonistic roles in cell proliferation and senescence, we speculated that both pathways may also exhibit opposing functions in oncogenic transformation. As reported previously,11 MEFs can be transformed by ectopic overexpression of oncogenic Ras12V plus c-myc (Figure 2a and b). Intriguingly, mkk7−/− MEFs were markedly resistant against Ras12V and c-myc-induced transformation (Figure 2a and b). Ectopic expression of MKK7 enhanced colony formation in control MEFs and restored oncogenic transformation of mkk7−/− MEFs (Figure 2a and b). p38-MAPK inhibition by MKK6-DN promoted cell transformation in control cells and, most importantly, in mkk7−/− MEFs (Figure 2a and b). In all our experiments p38-MAPK inhibition in mkk7−/− MEFs never reached transformation efficacies of MKK6-DN-transfected control MEFs or MKK7-transfected control and mkk7−/− MEFs. To extend these findings to another oncogenic cancer model, we examined the involvement of the MKK7-JNK and p38-MAPK pathways in Tpr-Met-induced cell transformation.12 Similar to Ras12V and c-myc, overexpression of oncogenic Tpr-Met triggered transformation in control MEFs, but to a much lesser extent in mkk7-deficient cells. Importantly, suppression of the p38-MAPK via MKK6-DN again promoted cell transformation in both control MEFs and restored oncogenic transformation in mkk7-deficient MEFs (Figure 2c). These results using different oncogenes show that the MKK7-JNK pathway is critical for cellular transformation, whereas p38-MAPK signaling negatively regulates oncogene-induced cellular transformation.
CDC2 is a potential target for molecular antagonisms
How can activation of two different cellular stress pathways result in opposite effects on cell cycle progression, senescence, or transformation in MEFs? We have recently identified the cell cycle kinase CDC2 as a molecular target for the MKK7-JNK signaling pathway in MEFs that links environmental stress and developmental cues to cell proliferation and senescence.6 Biochemically, CDC2 has also been identified as a downstream target for the p38-MAPK pathway.13 We therefore speculated that a molecular antagonism between these two different stress-signaling pathways might converge on CDC2. Since mkk7-deficient MEFs show reduced CDC2 expression and impaired CyclinB1 associated CDC2 kinase activity depending on the cell passage,6 we examined whether CyclinB1 associated CDC2 kinase activity can be rescued by inhibition of the p38-MAPK pathway. Whereas CDC2 expression and total CDC2 kinase activity were indeed markedly reduced in mkk7-null MEFs, inhibition of p38-MAPK resulted in increased CDC2 activity, without obvious effects on CDC2 expression (Figure 3a). Inhibition of p38-MAPK also resulted in increased CDC2 activity in mkk7+/− MEFs, suggesting that p38-MAPK can repress CDC2 activation even in the presence of MKK7 expression (Supplementary Figure 1b). In the same experimental system, we did not observe substantially altered CyclinD1-associated Cdk4 activity (Figure 3b). These results suggest that antagonistic regulation of CDC2 by MKK7-JNK and MKK3/6-p38 may be one of checkpoints by which different stress-signaling pathways control cell fate in MEFs.
Antagonism of the JNK and p38-MAPK pathways in hepatocyte proliferation and liver regeneration in vivo
To determine whether the observed molecular antagonism between MKK7-JNK and p38-MAPK pathways also occurs in other cell types, we analyzed mouse embryonic hepatoblasts. Inactivation of MKK7 in mice leads to embryonic lethality due to defective fetal liver formation around embryonic days 11.5–13.5 (Wada et al.6) and impaired hepatoblast proliferation (Figure 4a). Inhibition of p38-MAPKα/β enhanced hepatoblast proliferation from control mice and rescued the impaired proliferation of mkk7−/− hepatoblasts (Figure 4a). To determine whether functional antagonism between the MKK7-JNK and p38-MAPK pathways is limited to embryonic cells, that is, MEFs and hepatoblasts, or if such antagonism is also operational in adult tissue, liver regeneration (as stress) after partial hepatectomy was examined. Partial hepatectomy in wild-type animals triggers liver regeneration due to rapid re-entry of hepatocytes into the cell cycle, as determined by Ki67 staining (Figure 4b). Jun is a critical downstream target of MKK7-JNK: overexpression of Jun is sufficient to rescue defective proliferation and premature senescence in mkk7−/− MEFs,6 and inactivation of jun in adult mouse hepatocytes using Mx-Cre Junflox alleles results in defective hepatocyte proliferation (Figure 4b and Behrens et al.14). Since p38-MAPKα is the predominant isoform expressed in liver (http://www.genecards.org), we therefore generated adult mice with conditional deletion of both Jun and p38-MAPKα (Mx-Cre;Junflox/floxp38-MAPKαflox/flox) in hepatocytes. Intriguingly, in vivo hepatocyte proliferation was rescued in mice lacking both jun and p38-MAPKα (Figure 4b). We next analyzed CyclinB1-associated CDC2 kinase activity. Genetic deletion of both jun and p38-MAPKα resulted in strong induction of CyclinB1-associated kinase activity following partial hepatectomy (Supplementary Figure 2a and b). Of note, previous experiments have also reported reduced CyclinB1-associated kinase activity in jun mutant mice.14 Consistent among all samples analyzed, markedly enhanced CyclinB1-associated CDC2 kinase activity was observed in the absence of p38-MAPK (Supplementary Figure 2, and not shown). These results show that the two stress pathways exert antagonistic effects on cell fates in embryonic and adult tissues and multiple cell types.
Discussion
Our data indicate that the two distinct stress-signaling pathways, MKK3/MKK6-p38-MAPK versus MKK7-JNK, can exert opposite effects on cell cycle progression, cellular senescence, oncogenic transformation, and adult liver regeneration (Figure 4c). In response to environmental stress and oncogenic signals, the MKK7-JNK pathway promotes proliferation, transformation, and regeneration and prevents premature senescence. By contrast, activation of MKK3/6-p38-MAPK pathway antagonizes these MKK7-JNK functions. Although the roles of each MKK3/6-p38-MAPK and MKK7-JNK pathway in cell proliferation and senescence have been previously shown by us and other groups,6, 7, 8 the molecular cross-talks and the balance of the both pathways are not well described. Our data in fibroblasts and hepatocytes suggest that the two distinct stress-signaling pathways can both act on CDC2 with opposite effects. Regulation of CDC2 by MKK7-JNK and MKK3/6-p38 might be one mechanism by which stress signaling is coupled to cancer, cell cycle progression, or senescence. However, antagonistic cell fate regulations by the two stress pathways most likely also includes mechanisms other than CDC2, since many genes and proteins are regulated by MKK7-JNK-Jun and MKK3/6-p38-MAPKs.2
In conclusion, our results show that the stress kinase p38-MAPK pathway antagonizes MKK7-JNK functions in terms of cellular proliferation, senescence, oncogenic transformation, and liver regeneration. These data indicate that the balance between MKK7-JNK and MKK3/6-p38-MAPK signaling determines cell fate decisions in response to environmental and developmental stress in cancer, aging, and tissue regeneration.
Materials and Methods
Mice
mkk7-deficient MEFs were obtained as described.6 To disrupt the murine Jun and p38-MAPKα in liver, mice carrying junflox (Behrens et al.14) and p38-MAPKαflox (Engel et al.15) alleles were crossed to Mx1-Cre transgenic mice. The Cre transgene was induced in adult mice upon injections of polyinosinic–polycytidylic ribonucleic acid as described previously.14 Deletions of Jun and p38-MAPKα were confirmed by Western blot using Jun- and p38-MAPK-specific antibodies (Cell Signaling, data not shown). Partial hepatectomy was performed as described previously.16 Mouse experiments were performed according to institutional guidelines.
MEF cultures
MEFs were prepared from E11.5. embryos and maintained in DMEM with 10% FCS. Since mkk7+/+ and mkk7+/− MEFs behave equally in our experimental systems, mkk7+/− MEFs were used as controls. Cell proliferation in MEFs was determined using WST-1 (Roche). HA-tagged dominant-negative forms of MKK3 and MKK6 that carry inactivating AL mutations in their respective phosphorylation sites attenuate p38-MAPK activities, but not JNK activities in the presence of sorbitol stimuli.17 Dominant-negative MKK3 and MKK6 were ligated into a pBabe-puro vector to generate the pBabe-puro-MKK3DN and pBabe-puro-MKK6DN expression constructs. The expression of MKK3DN and MKK6DN was confirmed using an anti-HA antibody (Sigma; Supplementary Figure 1a). For ectopic gene expression in MEFs, the retroviral vectors pBabe-puro as control, pBabe-puro-MKK76, pBabe-puro-MKK3DN, or pBabe-puro-MKK6DN were transfected into phoenix-E packaging cells. MEFs were cultured in the supernatant of the packaging cells containing 5 μg/ml polybrene for 1 day and selected with 2.5 μg/ml puromycin for 2 days followed by 2 days of recovery. Empty pBabe-puro as control vector did not show any detectable effect on the phenotype of MEFs. SB202190 (Calbiochem) or the solvent DMSO were added into cultures as indicated in the figure legends. If not stated otherwise, MEFs at passages 4–5 were used in all experiments. To detect senescent cells, SA-β-gal staining was performed (Cell Signaling). It should be noted that all SA-β-gal-positive cells had the typical flattened cell morphology characteristic of senescent cells.18
Oncogenic transformation
MEFs were transformed with oncogenic Ras-V12 plus c-Myc or with oncogenic Tpr-Met using the retroviral vector pBabe as described above. Three thousand cells at passage 4 were plated on six-well plates and cultured for 21 days. The resultant foci were stained with Coomassie brilliant blue, and the numbers of foci were determined.
Kinase assays
To detect Cyclin-associated kinase activities, liver samples or MEFs (passages 2–4) were homogenized in lysis buffer containing 50 mM Tris-HCl (7.5), 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1% Tween-20, 10% glycerol, 1 mM NaF, 0.2 mM Na3VO4, and protease inhibitor cocktail (Roche), and CyclinD1 and CyclinB1 were immunoprecipitated from the supernatants at 4°C using specific antibodies (Santa Cruz). Kinase activities were determined using GST–Rb for CyclinD1 (Santa Cruz) and HistoneH1 for CyclinB1 (Roche) as substrates in the presence of [γ-32P]ATP. To detect JNK and p38-MAPK kinase activities, JNK and p38-MAPK were immunoprecipitated from MEF lysates using specific antibodies (Santa Cruz and Cell Signaling, respectively). Kinase activities were determined using GST-Jun and GST-ATF2 as substrates, in the presence of [γ-32P]ATP. Protein expression levels were determined using antibodies specific to CyclinB1, CyclinD1, Cdk4 (Santa Cruz), JNK, CDC2 (Cell Signaling), and actin (Sigma).
Abbreviations
- MEF:
-
mouse embryonic fibroblast
- DN:
-
dominant negative
References
Caffrey DR, O'Neill LA, Shields DC . The evolution of the MAP kinase pathways: coduplication of interacting proteins leads to new signaling cascades. J Mol Evol 1999; 49: 567–582.
Wada T, Penninger JM . Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838–2849.
Tibbles LA, Woodgett JR . The stress-activated protein kinase pathways. Cell Mol Life Sci 1999; 55: 1230–1254.
Chang L, Karin M . Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37–40.
Eferl R, Wagner EF . AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859–868.
Wada T, Joza N, Cheng HY, Sasaki T, Kozieradzki I, Bachmaier K et al. MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence. Nat Cell Biol 2004; 6: 215–226.
Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, Huang S et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002; 22: 3389–3403.
Matsumoto T, Turesson I, Book M, Gerwins P, Claesson-Welsh L . p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 2002; 156: 149–160.
Dimri GP . What has senescence got to do with cancer? Cancer Cell 2005; 7: 505–512.
Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003; 17: 1969–1978.
Land H, Parada LF, Weinberg RA . Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304: 596–602.
Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992; 12: 5152–5158.
Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, Yaffe MB . MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 2005; 17: 37–48.
Behrens A, Sibilia M, David JP, Mohle-Steinlein U, Tronche F, Schutz G et al. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J 2002; 21: 1782–1790.
Engel FB, Schebesta M, Duong MT, Lu G, Ren S, Madwed JB et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev 2005; 19: 1175–1187.
Servillo G, Della Fazia MA, Sassone-Corsi P . Transcription factor CREM coordinates the timing of hepatocyte proliferation in the regenerating liver. Genes Dev 1998; 12: 3639–3643.
Zanke BW, Rubie EA, Winnett E, Chan J, Randall S, Parsons M et al. Mammalian mitogen-activated protein kinase pathways are regulated through formation of specific kinase-activator complexes. J Biol Chem 1996; 271: 29876–29881.
Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363–9367.
Acknowledgements
We thank Jim Woodgett for critical comments and all members of our laboratories for fruitful discussions and suggestions. JMP is supported by grants from the Austrian National Bank, the Austrian Ministry of Science and Education, IMBA, and a EU Excellence Grant. LH is a recipient of an EMBO/Marie Curie fellowship. The IMP is supported by Boehringer Ingelheim.
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by C Duckett
Competing financial interests
The authors declare that there is no competing financial interest.
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Supplementary information
Rights and permissions
About this article
Cite this article
Wada, T., Stepniak, E., Hui, L. et al. Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ 15, 89–93 (2008). https://doi.org/10.1038/sj.cdd.4402222
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4402222
Keywords
This article is cited by
-
Neuronal MAP kinase p38α inhibits c-Jun N-terminal kinase to modulate anxiety-related behaviour
Scientific Reports (2018)
-
MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells
Oncogenesis (2017)
-
p38α MAPK antagonizing JNK to control the hepatic fat accumulation in pediatric patients onset intestinal failure
Cell Death & Disease (2017)
-
Doxorubicin cardiotoxicity and target cells: a broader perspective
Cardio-Oncology (2016)
-
Glutathione transferases P1/P2 regulate the timing of signaling pathway activations and cell cycle progression during mouse liver regeneration
Cell Death & Disease (2015)